CR20210521A - Glicoproteínas saliladas - Google Patents

Glicoproteínas saliladas

Info

Publication number
CR20210521A
CR20210521A CR20210521A CR20210521A CR20210521A CR 20210521 A CR20210521 A CR 20210521A CR 20210521 A CR20210521 A CR 20210521A CR 20210521 A CR20210521 A CR 20210521A CR 20210521 A CR20210521 A CR 20210521A
Authority
CR
Costa Rica
Prior art keywords
shear stress
stable
sialylated glycoproteins
pharmaceutical
preparations
Prior art date
Application number
CR20210521A
Other languages
English (en)
Inventor
Siddhesh D Patil
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CR20210521A publication Critical patent/CR20210521A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

Se describen preparaciones farmacéuticas que contienen inmunoglobulinas hipersialiladas. Las preparaciones son estables al esfuerzo de cizalla. Las composiciones farmacéuticas descritas en la presente descripción proporcionan composiciones de hsIgG farmacéuticamente aceptables que son estables contra el esfuerzo de cizalla (p. ej., no se forman un número significativo de partículas subvisibles cuando la formulación se somete a esfuerzo de cizalla, tal como agitación, por ejemplo, durante el envío) y, por lo tanto, pueden enviarse y manipularse en forma líquida
CR20210521A 2019-04-18 2020-04-17 Glicoproteínas saliladas CR20210521A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836016P 2019-04-18 2019-04-18
PCT/US2020/028863 WO2020215021A1 (en) 2019-04-18 2020-04-17 Sialylated glycoproteins

Publications (1)

Publication Number Publication Date
CR20210521A true CR20210521A (es) 2022-04-01

Family

ID=72837963

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210521A CR20210521A (es) 2019-04-18 2020-04-17 Glicoproteínas saliladas

Country Status (20)

Country Link
US (1) US20220211849A1 (es)
EP (1) EP3955962A4 (es)
JP (1) JP2022529168A (es)
KR (1) KR20220002963A (es)
CN (1) CN113795275A (es)
AU (1) AU2020259492A1 (es)
BR (1) BR112021020509A8 (es)
CA (1) CA3137101A1 (es)
CL (1) CL2021002668A1 (es)
CO (1) CO2021013926A2 (es)
CR (1) CR20210521A (es)
EA (1) EA202192860A1 (es)
EC (1) ECSP21078309A (es)
IL (1) IL287306A (es)
JO (1) JOP20210281A1 (es)
MX (1) MX2021012710A (es)
PE (1) PE20220383A1 (es)
SG (1) SG11202110942SA (es)
WO (1) WO2020215021A1 (es)
ZA (1) ZA202109184B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
JP2023551190A (ja) 2020-11-20 2023-12-07 モメンタ ファーマシューティカルズ インコーポレイテッド シアリル化糖タンパク質

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832756A (zh) * 2003-06-09 2006-09-13 约翰·A·麦金太尔 通过氧化还原反应改变血浆蛋白质结合专一性的方法
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
NZ599176A (en) * 2005-08-03 2014-04-30 Immunogen Inc Immunoconjugate formulations
EA023382B1 (ru) * 2009-05-27 2016-05-31 Бакстер Интернэшнл Инк. Способ получения высококонцентрированного препарата иммуноглобулина для подкожного применения
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
EP2900264A4 (en) * 2012-09-26 2016-05-25 Momenta Pharmaceuticals Inc GLYKOPROTEINZUBEREITUNGEN
EP3719122A1 (en) * 2013-05-02 2020-10-07 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
EP3004368B1 (en) * 2013-05-29 2019-09-18 F.Hoffmann-La Roche Ag Quantitative control of sialylation
EP3569224B1 (en) * 2017-01-11 2022-12-14 Celltrion Inc. Stable liquid formula

Also Published As

Publication number Publication date
BR112021020509A2 (pt) 2022-03-15
SG11202110942SA (en) 2021-11-29
IL287306A (en) 2021-12-01
EP3955962A1 (en) 2022-02-23
CN113795275A (zh) 2021-12-14
KR20220002963A (ko) 2022-01-07
CL2021002668A1 (es) 2022-05-27
EP3955962A4 (en) 2022-12-14
CO2021013926A2 (es) 2021-10-29
JOP20210281A1 (ar) 2023-01-30
ECSP21078309A (es) 2021-11-30
MX2021012710A (es) 2021-11-12
ZA202109184B (en) 2023-04-26
US20220211849A1 (en) 2022-07-07
JP2022529168A (ja) 2022-06-17
WO2020215021A1 (en) 2020-10-22
BR112021020509A8 (pt) 2023-01-10
CA3137101A1 (en) 2020-10-22
PE20220383A1 (es) 2022-03-18
EA202192860A1 (ru) 2021-12-23
AU2020259492A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2021012710A (es) Glicoproteinas sialiladas.
WO2016138030A3 (en) Compositions and methods for tolerizing the immune system to allergens
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
US8937102B2 (en) Fluid cocamide monoethanolamide concentrates and methods of preparation
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2015014513A (es) Composicion que comprende sulfato de salbutamol.
MX2022014216A (es) Nueva composicion farmaceutica para administracion de farmacos.
AU2018336623B2 (en) Methods of reducing particle formation and compositions formed thereby
BR112015019580A2 (pt) processo para preparar uma solução aquosa, solução aquosa, medicamento, alimento, ingrediente de alimento ou suplemento alimentício e método para reduzir a assimilação calórica
MX2021004551A (es) Composicion farmaceutica para el tratamiento de la anemia aplasica.
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
WO2019031898A3 (ko) 약학 조성물 및 이의 제조방법
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
CN103980516A (zh) 一种涂布型气相防锈剂薄膜及其制备方法
SG10201807034XA (en) A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
BR112017019753A2 (pt) uso de composições de astaxantina, composição, processo para preparação de um produto alimentício ou ração, e, preparação medicinal
MX2019013053A (es) Composicion que contiene ciclodextrina y busulfan.
SG10201802129QA (en) A pharmaceutical composition for neuropathic pain
MX2023008569A (es) Formulaciones farmaceuticas mejoradas.
GB850006A (en) Improvements in or relating to derivatives of nitrofuran
CR20220620A (es) Composición farmacéutica acuosa de levilimab y su uso
MX2022008034A (es) Composiciones y extractos antioxidantes.
MX2020010259A (es) Preparacion farmaceutica.
KR102106138B1 (ko) 마크로캡슐 운송을 위한 포장방법
KR101779676B1 (ko) 균일한 혼합도의 투석액 조제용 조성물의 제조방법